ArticleMolecular and cellular biology1998
In vitro genetic analysis of the RNA binding site of vigilin, a multi-KH-domain protein.
Article in Molecular and cellular biology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 53 citations in OpenAlex.
- Spatiotemporal analysis of dystrophin expression during muscle repair.Skeletal muscle · 2025Article
- Autism-Associated Vigilin Depletion Impairs DNA Damage Repair.Molecular and cellular biology · 2021Article
- Mechanistic studies of a small-molecule modulator of SMN2 splicing.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Conserved regions of the DMD 3' UTR regulate translation and mRNA abundance in cultured myotubes.Neuromuscular disorders : NMD · 2014Article
- Identification of RNA-protein interaction networks involved in the norovirus life cycle.Journal of virology · 2012Article
- Posttranscriptional suppression of proto-oncogene c-fms expression by vigilin in breast cancer.Molecular and cellular biology · 2011Article
- Distinct roles for Khd1p in the localization and expression of bud-localized mRNAs in yeast.RNA (New York, N.Y.) · 2008Article
- On the mechanism of induction of heterochromatin by the RNA-binding protein vigilin.RNA (New York, N.Y.) · 2008Article
- The aryl hydrocarbon receptor-mediated disruption of vitellogenin synthesis in the fish liver: Cross-talk between AHR- and ERalpha-signalling pathways.Comparative hepatology · 2004Article
- Determination and augmentation of RNA sequence specificity of the Nova K-homology domains.Nucleic acids research · 2004Article
- RNAi-mediated depletion of the 15 KH domain protein, vigilin, induces death of dividing and non-dividing human cells but does not initially inhibit protein synthesis.Nucleic acids research · 2003Article
- An in vitro-selected RNA-binding site for the KH domain protein PSI acts as a splicing inhibitor element.RNA (New York, N.Y.) · 2001Article
- Recognition of RNA branch point sequences by the KH domain of splicing factor 1 (mammalian branch point binding protein) in a splicing factor complex.Molecular and cellular biology · 2001Article
- Vigilin binding selectively inhibits cleavage of the vitellogenin mRNA 3'-untranslated region by the mRNA endonuclease polysomal ribonuclease 1.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
- DDP1, a heterochromatin-associated multi-KH-domain protein of Drosophila melanogaster, interacts specifically with centromeric satellite DNA sequences.Molecular and cellular biology · 2000Article
- Export and transport of tRNA are coupled to a multi-protein complex.The Biochemical journal · 2000Article
- Dissecting FMR1, the protein responsible for fragile X syndrome, in its structural and functional domains.RNA (New York, N.Y.) · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The function(s) and RNA binding properties of vigilin, a ubiquitous protein with 14 KH domains, remain largely obscure. We recently showed that vigilin is the estrogen-inducible protein in polysome extracts which binds specifically to a segment of the 3' untranslated region (UTR) of estrogen-stabilized vitellogenin mRNA. In order to identify consensus mRNA sequences and structures important in binding of vigilin to RNA, before vigilin was purified, we developed a modified in vitro genetic selection protocol. We subsequently validated our selection procedure, which employed crude polysome extracts, by testing natural and in vitro-selected RNAs with purified recombinant vigilin. Most of the selected up-binding mutants exhibited hypermutation of G residues leading to a largely unstructured, single-stranded region containing multiple conserved (A)nCU and UC(A)n motifs. All eight of the selected down-binding mutants contained a mutation in the sequence (A)nCU. Deletion analysis indicated that approximately 75 nucleotides are required for maximal binding. Using this information, we predicted and subsequently identified a strong vigilin binding site near the 3' end of human dystrophin mRNA. RNA sequences from the 3' UTRs of transferrin receptor and estrogen receptor, which lack strong homology to the selected sequences, did not bind vigilin. These studies describe an aproach to identifying long RNA binding sites and describe sequence and structural requirements for interaction of vigilin with RNAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.